Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunogenicity and Safety of One Dose of HPV Vaccine
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Shanghai BravoBio Co., Ltd. | Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Clinical Trial of a Candidate HPV Vaccine
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Shanghai BravoBio Co., Ltd. | Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 29, 2021
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Details : ISA101b is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 03, 2019
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
Details : ISA101b is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 13, 2018
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 21, 2017
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 15, 2016
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Dysplasia.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 23, 2013
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Dysplasia.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 28, 2012
Lead Product(s) : Human Papillomavirus Vaccine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Xiamen Innovax Biotech | Beijing Wantai Biological Pharmacy Enterprise | Ministry of Science and Technology, China
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
